Breaking News

Janssen Establishes Trial Investigator Databank

November 15, 2012

Aims to reduce work involved in identifying clinical trial sites

Janssen Research & Development, a J&J unit, has established a global cross-pharmaceutical Investigator Databank designed to improve efficiencies of industry-sponsored clinical trials. Merck and Eli Lilly and Co. are the first two companies to join Janssen in this effort. It is anticipated that the Investigator Databank will be operational by the end of the year. It will be hosted by DrugDev.org, an independent, third party with expertise in clinical trial IT and investigator community management.
 
The new Investigator Databank will serve as a repository housing key information about clinical trial sites, such as infrastructure and Good Clinical Practice (GCP) training records, with the goal of allowing participating pharma companies to reduce time-consuming and redundant administrative work involved in identifying clinical trial sites. 
 
“The current clinical trial environment is inefficient, costly and unsustainable. The Investigator Databank can help expedite the process to achieve our most important goal — to deliver high-quality, effective novel medicines to the patients who are waiting for them,” said Andreas Koester, MD, Ph.D., head, Clinical Trial Innovation/External Alliances, Janssen R&D. “We are enthusiastic about working with other industry leaders to collectively apply our expertise, capabilities and shared passion for advancing science and improving lives.”

Related Compliance:

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research